| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medicare | 7 | 2023 | 219 | 3.100 |
Why?
|
| Reimbursement, Incentive | 5 | 2023 | 16 | 2.730 |
Why?
|
| Sarcoma | 20 | 2024 | 92 | 2.610 |
Why?
|
| Pathology | 4 | 2020 | 20 | 2.520 |
Why?
|
| Quality of Health Care | 4 | 2020 | 148 | 2.340 |
Why?
|
| Graft vs Host Disease | 11 | 2022 | 39 | 2.300 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2022 | 105 | 1.510 |
Why?
|
| Esophageal Neoplasms | 2 | 2026 | 39 | 1.130 |
Why?
|
| Colorectal Neoplasms | 3 | 2026 | 219 | 1.070 |
Why?
|
| Automation, Laboratory | 1 | 2026 | 2 | 0.950 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2026 | 43 | 0.940 |
Why?
|
| Immunohistochemistry | 7 | 2025 | 543 | 0.900 |
Why?
|
| DNA Mismatch Repair | 2 | 2024 | 10 | 0.890 |
Why?
|
| Humans | 65 | 2026 | 32274 | 0.860 |
Why?
|
| Liver Neoplasms | 6 | 2025 | 164 | 0.850 |
Why?
|
| Microsatellite Instability | 1 | 2024 | 5 | 0.850 |
Why?
|
| Soft Tissue Neoplasms | 6 | 2024 | 44 | 0.840 |
Why?
|
| Stomach Neoplasms | 1 | 2026 | 113 | 0.840 |
Why?
|
| Endometrial Neoplasms | 1 | 2024 | 49 | 0.810 |
Why?
|
| Physicians | 2 | 2023 | 163 | 0.780 |
Why?
|
| Gastrointestinal Diseases | 3 | 2018 | 50 | 0.760 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2025 | 65 | 0.710 |
Why?
|
| Breast Neoplasms | 3 | 2026 | 762 | 0.710 |
Why?
|
| United States | 11 | 2026 | 4072 | 0.700 |
Why?
|
| Prospective Payment System | 2 | 2020 | 11 | 0.670 |
Why?
|
| Mice | 29 | 2025 | 2571 | 0.650 |
Why?
|
| Viremia | 1 | 2018 | 6 | 0.570 |
Why?
|
| Cytosine | 1 | 2018 | 10 | 0.570 |
Why?
|
| Medulloblastoma | 1 | 2018 | 8 | 0.570 |
Why?
|
| Adenoviridae Infections | 1 | 2018 | 14 | 0.560 |
Why?
|
| Adenoviridae | 1 | 2018 | 68 | 0.550 |
Why?
|
| Bone Neoplasms | 4 | 2023 | 116 | 0.520 |
Why?
|
| Animals | 34 | 2025 | 8199 | 0.510 |
Why?
|
| Fee-for-Service Plans | 1 | 2017 | 14 | 0.510 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 395 | 0.480 |
Why?
|
| Delivery of Health Care | 2 | 2017 | 167 | 0.480 |
Why?
|
| Adenocarcinoma | 4 | 2021 | 297 | 0.470 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2016 | 34 | 0.470 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2025 | 81 | 0.470 |
Why?
|
| Female | 32 | 2026 | 19942 | 0.450 |
Why?
|
| Reproducibility of Results | 4 | 2026 | 757 | 0.440 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2019 | 16 | 0.400 |
Why?
|
| Chondrosarcoma | 2 | 2023 | 10 | 0.390 |
Why?
|
| Pathology, Clinical | 3 | 2024 | 11 | 0.390 |
Why?
|
| Aged | 20 | 2026 | 10260 | 0.360 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2012 | 3 | 0.360 |
Why?
|
| Medicaid | 2 | 2023 | 101 | 0.340 |
Why?
|
| Point Mutation | 2 | 2025 | 29 | 0.330 |
Why?
|
| T-Lymphocytes | 4 | 2022 | 140 | 0.320 |
Why?
|
| Intestinal Neoplasms | 2 | 2024 | 3 | 0.320 |
Why?
|
| Predictive Value of Tests | 5 | 2026 | 883 | 0.320 |
Why?
|
| Disease Models, Animal | 10 | 2020 | 1083 | 0.320 |
Why?
|
| Cell Line, Tumor | 9 | 2020 | 729 | 0.310 |
Why?
|
| Intestine, Small | 2 | 2024 | 43 | 0.310 |
Why?
|
| Male | 26 | 2026 | 19437 | 0.310 |
Why?
|
| Retrospective Studies | 11 | 2025 | 3624 | 0.310 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2018 | 90 | 0.300 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 146 | 0.300 |
Why?
|
| Nerve Sheath Neoplasms | 2 | 2020 | 10 | 0.290 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2025 | 1223 | 0.290 |
Why?
|
| Sarcoma, Experimental | 2 | 2019 | 7 | 0.290 |
Why?
|
| Reperfusion Injury | 2 | 2023 | 60 | 0.290 |
Why?
|
| MicroRNAs | 3 | 2015 | 181 | 0.290 |
Why?
|
| Skin Neoplasms | 3 | 2023 | 220 | 0.280 |
Why?
|
| Neurofibromatosis 1 | 2 | 2018 | 11 | 0.270 |
Why?
|
| Middle Aged | 19 | 2026 | 11848 | 0.260 |
Why?
|
| Mice, Transgenic | 9 | 2019 | 257 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2018 | 19 | 0.250 |
Why?
|
| Occult Blood | 1 | 2026 | 12 | 0.250 |
Why?
|
| Hemangiosarcoma | 2 | 2017 | 11 | 0.240 |
Why?
|
| Cost Savings | 1 | 2026 | 34 | 0.230 |
Why?
|
| Keratin-7 | 1 | 2025 | 2 | 0.230 |
Why?
|
| Keratin-20 | 1 | 2025 | 6 | 0.230 |
Why?
|
| Early Detection of Cancer | 1 | 2026 | 100 | 0.230 |
Why?
|
| RNA Splicing | 1 | 2025 | 8 | 0.220 |
Why?
|
| Cell Proliferation | 5 | 2019 | 603 | 0.220 |
Why?
|
| Diagnostic Imaging | 2 | 2016 | 89 | 0.220 |
Why?
|
| Tuberculosis, Osteoarticular | 1 | 2024 | 2 | 0.210 |
Why?
|
| Cell Cycle Proteins | 1 | 2024 | 52 | 0.210 |
Why?
|
| Sarcoma, Small Cell | 1 | 2024 | 1 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2019 | 258 | 0.210 |
Why?
|
| Wrist | 1 | 2024 | 44 | 0.210 |
Why?
|
| Neoplasms | 2 | 2025 | 754 | 0.210 |
Why?
|
| Osteomyelitis | 1 | 2024 | 26 | 0.210 |
Why?
|
| Herpesviridae | 1 | 2023 | 1 | 0.200 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2023 | 1 | 0.200 |
Why?
|
| Myoepithelioma | 1 | 2023 | 3 | 0.200 |
Why?
|
| Receptors, Steroid | 1 | 2023 | 12 | 0.200 |
Why?
|
| Mice, Inbred C57BL | 8 | 2021 | 792 | 0.190 |
Why?
|
| Radiation Injuries | 1 | 2023 | 85 | 0.190 |
Why?
|
| Phenotype | 1 | 2024 | 621 | 0.190 |
Why?
|
| Liver Transplantation | 1 | 2023 | 185 | 0.190 |
Why?
|
| Bone Marrow Transplantation | 2 | 2021 | 68 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 2 | 2015 | 131 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2025 | 907 | 0.190 |
Why?
|
| Cholangiocarcinoma | 1 | 2022 | 12 | 0.180 |
Why?
|
| Motivation | 1 | 2023 | 120 | 0.180 |
Why?
|
| Mutation | 3 | 2019 | 497 | 0.180 |
Why?
|
| Bile Duct Neoplasms | 1 | 2022 | 33 | 0.180 |
Why?
|
| Stromal Cells | 2 | 2020 | 66 | 0.180 |
Why?
|
| Mice, Nude | 6 | 2019 | 285 | 0.180 |
Why?
|
| Radiation Tolerance | 2 | 2019 | 27 | 0.180 |
Why?
|
| Leukemia | 1 | 2022 | 38 | 0.180 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2021 | 5 | 0.180 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2019 | 17 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 63 | 0.170 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2019 | 60 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 2021 | 1 | 0.170 |
Why?
|
| Receptor, Notch2 | 1 | 2021 | 1 | 0.170 |
Why?
|
| B-Cell Activating Factor | 1 | 2021 | 4 | 0.170 |
Why?
|
| Rotator Cuff | 1 | 2021 | 75 | 0.170 |
Why?
|
| Adult | 11 | 2025 | 9256 | 0.170 |
Why?
|
| Signal Transduction | 6 | 2023 | 727 | 0.160 |
Why?
|
| Contractile Proteins | 1 | 2020 | 6 | 0.160 |
Why?
|
| Drug Carriers | 1 | 2020 | 22 | 0.160 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 74 | 0.160 |
Why?
|
| Gallbladder Neoplasms | 1 | 2020 | 35 | 0.160 |
Why?
|
| Disease-Free Survival | 4 | 2023 | 324 | 0.160 |
Why?
|
| Doxorubicin | 1 | 2020 | 76 | 0.160 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2020 | 100 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2020 | 381 | 0.150 |
Why?
|
| Radiology Information Systems | 1 | 2019 | 12 | 0.150 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2019 | 3 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2019 | 43 | 0.150 |
Why?
|
| Genetic Engineering | 2 | 2016 | 22 | 0.150 |
Why?
|
| Neutrophils | 1 | 2019 | 120 | 0.140 |
Why?
|
| Indazoles | 1 | 2018 | 4 | 0.140 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2018 | 13 | 0.140 |
Why?
|
| Pyrazines | 1 | 2018 | 14 | 0.140 |
Why?
|
| Neoplasm, Residual | 2 | 2016 | 26 | 0.140 |
Why?
|
| Octreotide | 1 | 2018 | 6 | 0.140 |
Why?
|
| Embolization, Therapeutic | 1 | 2019 | 81 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 443 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 556 | 0.140 |
Why?
|
| Abdominal Wall | 1 | 2018 | 24 | 0.140 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 31 | 0.140 |
Why?
|
| Colon | 1 | 2018 | 72 | 0.140 |
Why?
|
| Integrases | 1 | 2017 | 3 | 0.130 |
Why?
|
| Pathology, Surgical | 1 | 2017 | 2 | 0.130 |
Why?
|
| PAX7 Transcription Factor | 2 | 2014 | 10 | 0.130 |
Why?
|
| Antibody Specificity | 1 | 2017 | 17 | 0.130 |
Why?
|
| Epitopes | 1 | 2017 | 26 | 0.130 |
Why?
|
| Alleles | 4 | 2024 | 250 | 0.130 |
Why?
|
| Physician's Role | 1 | 2017 | 41 | 0.130 |
Why?
|
| Lung Neoplasms | 3 | 2015 | 423 | 0.130 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 89 | 0.130 |
Why?
|
| Genetic Markers | 1 | 2017 | 124 | 0.130 |
Why?
|
| Myelolipoma | 1 | 2016 | 2 | 0.120 |
Why?
|
| Health Care Reform | 1 | 2017 | 45 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 157 | 0.120 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2016 | 17 | 0.120 |
Why?
|
| Cecal Neoplasms | 1 | 2016 | 2 | 0.120 |
Why?
|
| Propensity Score | 1 | 2016 | 47 | 0.120 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2016 | 19 | 0.120 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2016 | 7 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 19 | 0.120 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2016 | 14 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 108 | 0.120 |
Why?
|
| Peptide Hydrolases | 1 | 2016 | 17 | 0.120 |
Why?
|
| Algorithms | 1 | 2019 | 536 | 0.120 |
Why?
|
| Swine | 3 | 2023 | 228 | 0.120 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 93 | 0.120 |
Why?
|
| Skin | 2 | 2018 | 212 | 0.120 |
Why?
|
| Biopsy | 5 | 2015 | 252 | 0.120 |
Why?
|
| Fluorescent Dyes | 1 | 2016 | 52 | 0.120 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2015 | 18 | 0.120 |
Why?
|
| Laser Therapy | 1 | 2016 | 51 | 0.110 |
Why?
|
| Ligaments | 1 | 2015 | 12 | 0.110 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2016 | 65 | 0.110 |
Why?
|
| Melanoma | 1 | 2017 | 166 | 0.110 |
Why?
|
| Cryosurgery | 1 | 2015 | 25 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 24 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 245 | 0.110 |
Why?
|
| Gallbladder | 1 | 2015 | 3 | 0.110 |
Why?
|
| Intestinal Diseases | 1 | 2015 | 17 | 0.110 |
Why?
|
| Muscle, Skeletal | 2 | 2020 | 520 | 0.110 |
Why?
|
| Gallbladder Diseases | 1 | 2015 | 8 | 0.110 |
Why?
|
| Mouth Diseases | 1 | 2015 | 21 | 0.110 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2015 | 21 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2018 | 1233 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 109 | 0.110 |
Why?
|
| Liver Diseases | 1 | 2015 | 72 | 0.110 |
Why?
|
| Cartilage, Articular | 1 | 2015 | 72 | 0.110 |
Why?
|
| Dermatofibrosarcoma | 1 | 2014 | 3 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 3898 | 0.110 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2014 | 6 | 0.110 |
Why?
|
| Choristoma | 1 | 2014 | 14 | 0.100 |
Why?
|
| Catheter Ablation | 1 | 2015 | 113 | 0.100 |
Why?
|
| Cell Cycle | 2 | 2024 | 75 | 0.100 |
Why?
|
| MyoD Protein | 1 | 2013 | 10 | 0.100 |
Why?
|
| Rhabdomyosarcoma | 1 | 2013 | 7 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 502 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2024 | 18 | 0.100 |
Why?
|
| Mesenchymoma | 1 | 2013 | 1 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2015 | 193 | 0.100 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2013 | 3 | 0.100 |
Why?
|
| Myoblasts, Skeletal | 1 | 2013 | 21 | 0.100 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2013 | 6 | 0.100 |
Why?
|
| Hypophosphatemia | 1 | 2013 | 6 | 0.100 |
Why?
|
| Scleroderma, Systemic | 1 | 2013 | 8 | 0.100 |
Why?
|
| Prognosis | 3 | 2024 | 1534 | 0.100 |
Why?
|
| Plasma Cells | 1 | 2013 | 12 | 0.100 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 18 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 42 | 0.100 |
Why?
|
| Skin Diseases | 1 | 2015 | 135 | 0.100 |
Why?
|
| Carbon | 1 | 2013 | 13 | 0.100 |
Why?
|
| Chemokine CCL2 | 1 | 2013 | 48 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 96 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 312 | 0.100 |
Why?
|
| Chromogenic Compounds | 1 | 2012 | 2 | 0.100 |
Why?
|
| Choline | 1 | 2013 | 18 | 0.100 |
Why?
|
| Colonic Polyps | 1 | 2012 | 17 | 0.100 |
Why?
|
| Light | 1 | 2012 | 35 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 129 | 0.090 |
Why?
|
| Pancreas | 1 | 2013 | 107 | 0.090 |
Why?
|
| Colonoscopy | 1 | 2012 | 45 | 0.090 |
Why?
|
| Adenoma | 1 | 2012 | 34 | 0.090 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2012 | 4 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2012 | 34 | 0.090 |
Why?
|
| Fatty Liver | 1 | 2013 | 70 | 0.090 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2012 | 19 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2013 | 224 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 70 | 0.090 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2012 | 46 | 0.090 |
Why?
|
| Gene Fusion | 2 | 2023 | 4 | 0.090 |
Why?
|
| Liver | 3 | 2023 | 492 | 0.090 |
Why?
|
| Fibroblasts | 2 | 2025 | 119 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2012 | 39 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2019 | 3416 | 0.090 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 222 | 0.090 |
Why?
|
| Radiosurgery | 1 | 2015 | 355 | 0.090 |
Why?
|
| Adolescent | 4 | 2024 | 3517 | 0.090 |
Why?
|
| Hyalin | 2 | 2021 | 2 | 0.090 |
Why?
|
| Young Adult | 4 | 2024 | 2648 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2016 | 823 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 221 | 0.080 |
Why?
|
| Survival Rate | 3 | 2017 | 893 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 1050 | 0.070 |
Why?
|
| Tissue Distribution | 2 | 2020 | 64 | 0.070 |
Why?
|
| Observer Variation | 2 | 2020 | 96 | 0.070 |
Why?
|
| Radiotherapy | 2 | 2019 | 92 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2020 | 131 | 0.070 |
Why?
|
| Fibrosis | 2 | 2021 | 126 | 0.070 |
Why?
|
| Transplantation, Homologous | 2 | 2021 | 158 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2021 | 196 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2020 | 368 | 0.060 |
Why?
|
| Postal Service | 1 | 2026 | 10 | 0.060 |
Why?
|
| Imidazoles | 2 | 2018 | 97 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2020 | 854 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 114 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2020 | 454 | 0.060 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2025 | 1 | 0.060 |
Why?
|
| Gene Deletion | 2 | 2015 | 66 | 0.050 |
Why?
|
| Enterococcus faecalis | 1 | 2024 | 12 | 0.050 |
Why?
|
| Antitubercular Agents | 1 | 2024 | 7 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2019 | 839 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2024 | 2 | 0.050 |
Why?
|
| Cell Movement | 2 | 2015 | 167 | 0.050 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2024 | 34 | 0.050 |
Why?
|
| Mass Screening | 1 | 2026 | 256 | 0.050 |
Why?
|
| ras Proteins | 2 | 2014 | 10 | 0.050 |
Why?
|
| Organ Preservation | 1 | 2023 | 37 | 0.050 |
Why?
|
| Perfusion | 1 | 2023 | 75 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2015 | 193 | 0.050 |
Why?
|
| Nucleotidyltransferases | 1 | 2023 | 8 | 0.050 |
Why?
|
| Intestines | 1 | 2023 | 63 | 0.050 |
Why?
|
| DNA Damage | 1 | 2023 | 90 | 0.050 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2023 | 1 | 0.050 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2023 | 3 | 0.050 |
Why?
|
| Prebiotics | 1 | 2022 | 4 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2023 | 82 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 149 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2022 | 6 | 0.050 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2022 | 7 | 0.050 |
Why?
|
| Glycolysis | 1 | 2022 | 17 | 0.050 |
Why?
|
| Infarction | 1 | 2021 | 7 | 0.040 |
Why?
|
| Gastroenterology | 1 | 2021 | 3 | 0.040 |
Why?
|
| Necrosis | 1 | 2021 | 54 | 0.040 |
Why?
|
| Contrast Media | 1 | 2022 | 136 | 0.040 |
Why?
|
| Tendons | 1 | 2021 | 50 | 0.040 |
Why?
|
| Skin Transplantation | 1 | 2021 | 50 | 0.040 |
Why?
|
| Isoantigens | 1 | 2021 | 3 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 62 | 0.040 |
Why?
|
| Isoantibodies | 1 | 2021 | 11 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2021 | 72 | 0.040 |
Why?
|
| Foot Bones | 1 | 2020 | 1 | 0.040 |
Why?
|
| Dactinomycin | 1 | 2020 | 13 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2020 | 6 | 0.040 |
Why?
|
| Vincristine | 1 | 2020 | 24 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 94 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 37 | 0.040 |
Why?
|
| Organophosphorus Compounds | 1 | 2020 | 30 | 0.040 |
Why?
|
| Etoposide | 1 | 2020 | 38 | 0.040 |
Why?
|
| Micelles | 1 | 2020 | 7 | 0.040 |
Why?
|
| Foot | 1 | 2020 | 40 | 0.040 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2020 | 26 | 0.040 |
Why?
|
| Collagen | 1 | 2021 | 229 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2020 | 56 | 0.040 |
Why?
|
| Nanoparticles | 1 | 2020 | 52 | 0.040 |
Why?
|
| Embryo, Mammalian | 1 | 2019 | 31 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 773 | 0.040 |
Why?
|
| Peptides | 1 | 2020 | 127 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 46 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 99 | 0.040 |
Why?
|
| Whole-Body Irradiation | 1 | 2019 | 58 | 0.040 |
Why?
|
| Eye | 1 | 2018 | 17 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2015 | 2316 | 0.040 |
Why?
|
| Morpholines | 1 | 2018 | 47 | 0.040 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2018 | 7 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 70 | 0.040 |
Why?
|
| Neurofibromin 1 | 1 | 2018 | 2 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2018 | 9 | 0.040 |
Why?
|
| Pyridones | 1 | 2018 | 10 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2018 | 7 | 0.030 |
Why?
|
| Triazines | 1 | 2018 | 8 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 11 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2018 | 36 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 79 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 200 | 0.030 |
Why?
|
| Benzamides | 1 | 2018 | 60 | 0.030 |
Why?
|
| Endoscopy, Digestive System | 1 | 2017 | 11 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2017 | 16 | 0.030 |
Why?
|
| Equipment and Supplies | 1 | 2017 | 15 | 0.030 |
Why?
|
| Gene Expression | 1 | 2019 | 345 | 0.030 |
Why?
|
| Electroporation | 1 | 2017 | 15 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 106 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2017 | 41 | 0.030 |
Why?
|
| Neurilemmoma | 1 | 2017 | 17 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 477 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 253 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 285 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2017 | 413 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 591 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 86 | 0.030 |
Why?
|
| Pelvis | 1 | 2016 | 67 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 757 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 99 | 0.030 |
Why?
|
| Metabolome | 1 | 2016 | 37 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 73 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2016 | 125 | 0.030 |
Why?
|
| Mitochondrial Size | 1 | 2015 | 2 | 0.030 |
Why?
|
| Elastic Modulus | 1 | 2015 | 29 | 0.030 |
Why?
|
| Tensile Strength | 1 | 2015 | 60 | 0.030 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2015 | 3 | 0.030 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2015 | 12 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2015 | 52 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2016 | 90 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 79 | 0.030 |
Why?
|
| Consensus | 1 | 2015 | 87 | 0.030 |
Why?
|
| Base Sequence | 1 | 2015 | 252 | 0.030 |
Why?
|
| Quinolines | 1 | 2015 | 29 | 0.030 |
Why?
|
| Cell Death | 1 | 2015 | 79 | 0.030 |
Why?
|
| Urethane | 1 | 2014 | 3 | 0.030 |
Why?
|
| Cardiotoxins | 1 | 2014 | 9 | 0.030 |
Why?
|
| Cysts | 1 | 2015 | 17 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 203 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2014 | 63 | 0.030 |
Why?
|
| Carcinogens | 1 | 2014 | 36 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 461 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 179 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2014 | 23 | 0.030 |
Why?
|
| Factor XIIIa | 1 | 2014 | 3 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1241 | 0.030 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2014 | 4 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2015 | 144 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2014 | 22 | 0.030 |
Why?
|
| S100 Proteins | 1 | 2014 | 20 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 48 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2014 | 14 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2014 | 84 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 232 | 0.030 |
Why?
|
| Osteomalacia | 1 | 2013 | 1 | 0.030 |
Why?
|
| Phosphates | 1 | 2013 | 26 | 0.020 |
Why?
|
| Muscle Development | 1 | 2013 | 52 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 124 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 37 | 0.020 |
Why?
|
| Mitochondria | 1 | 2015 | 211 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 28 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 96 | 0.020 |
Why?
|
| Lymphocyte Depletion | 1 | 2012 | 18 | 0.020 |
Why?
|
| RNA | 1 | 2013 | 94 | 0.020 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2012 | 18 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2014 | 256 | 0.020 |
Why?
|
| Luciferases | 1 | 2012 | 33 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2012 | 36 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 25 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2012 | 63 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 287 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2012 | 61 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 34 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2012 | 78 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 183 | 0.020 |
Why?
|
| Infant | 1 | 2015 | 1010 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 425 | 0.020 |
Why?
|
| Pancreas Transplantation | 1 | 2013 | 245 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 702 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 2240 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 553 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2012 | 461 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 363 | 0.020 |
Why?
|
| North Carolina | 1 | 2012 | 1300 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 2204 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 595 | 0.020 |
Why?
|
| Risk Factors | 1 | 2013 | 3934 | 0.010 |
Why?
|